LONG® EGF is a recombinant analog of human epidermal growth factor (EGF) used in regulatory approved cell-based therapies. It was developed as a supplement for use in therapeutic cell culture applications as a like-for-like replacement for native EGF or recombinant human EGF (hEGF). The source is a proprietary Escherichia coli fermentation process, manufactured without the use of animal- or human-derived materials.
Lyophilized powder dried from 10 mM hydrochloric acid (HCl) in an atmosphere of nitrogen at a slight vacuum (~25 kPa)
Under a quality management system that is ISO:9001 certified and based on EU GMP
Proprietary e.coli manufacturing process
Positive effects have been observed with LONG®R3 IGF-I in HEK293, MDCK and HeLa cell lines
Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, to ensure business continuity for our customers.
LONG® EGF can be used as a supplement for serum-free or low serum culture.
Recombinant LONG® EGF acts via the Erb-1 receptor and has applications in fibroblast cell culture. Synergistic effects have been observed with LONG®R3 IGF-I in HEK293, MDCK and HeLa cell lines.
LONG® EGF is used across a wide range of customer-driven applications, including: